Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Total Non-Current Liabilities of $344.5 million for Q1 2026, down 0.76% year-over-year from $347.2 million in Q1 2025, and up 8.46% quarter-over-quarter from $317.7 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $344.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 0.76% year-over-year to $344.5 million; the TTM figure through Mar 2026 stood at $344.5 million (down 0.76% YoY), while the FY2025 annual figure was $317.7 million, down 27.29% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $344.5 million, up from $317.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $436.9 million in Q4 2024, with the low at $170.3 million in Q3 2022.
- The 5-year median for Total Non-Current Liabilities is $317.7 million (2025), against an average of $302.9 million.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 69.38% in 2023, then retreated 27.29% in 2025.
- Acadia Pharmaceuticals' Total Non-Current Liabilities stood at $178.3 million in 2022, then soared by 69.38% to $302.1 million in 2023, then surged by 44.65% to $436.9 million in 2024, then declined by 27.29% to $317.7 million in 2025, then increased by 8.46% to $344.5 million in 2026.
- Business Quant data shows ACAD's Total Non-Current Liabilities at $344.5 million in Q1 2026, $317.7 million in Q4 2025, and $399.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 420.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 420.98 Mn |
| Mar 31, 2026 | 344.53 Mn |
| Dec 31, 2025 | 317.67 Mn |
| Sep 30, 2025 | 399.61 Mn |
| Jun 30, 2025 | 374.63 Mn |
| Mar 31, 2025 | 347.16 Mn |
| Dec 31, 2024 | 436.91 Mn |
| Sep 30, 2024 | 384.37 Mn |
| Jun 30, 2024 | 385.04 Mn |
| Mar 31, 2024 | 390.86 Mn |
| Dec 31, 2023 | 302.05 Mn |
| Sep 30, 2023 | 257.71 Mn |
| Jun 30, 2023 | 237.72 Mn |
| Mar 31, 2023 | 275.74 Mn |
| Dec 31, 2022 | 178.33 Mn |
| Sep 30, 2022 | 170.34 Mn |
| Jun 30, 2022 | 172.37 Mn |
| Mar 31, 2022 | 175.08 Mn |
| Dec 31, 2021 | 158.63 Mn |
| Sep 30, 2021 | 145.90 Mn |